Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 2
1959 2
1999 3
2000 1
2001 3
2002 2
2003 3
2004 1
2005 5
2006 3
2007 1
2008 1
2009 1
2010 1
2015 1
2016 2
2017 2
2020 3
2021 5
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Viral and Clinical Oncology of Head and Neck Cancers.
Goon P, Schürmann M, Oppel F, Shao S, Schleyer S, Pfeiffer CJ, Todt I, Brasch F, Scholtz LU, Göerner M, Sudhoff H. Goon P, et al. Among authors: goerner m. Curr Oncol Rep. 2022 Jul;24(7):929-942. doi: 10.1007/s11912-022-01263-7. Epub 2022 Mar 26. Curr Oncol Rep. 2022. PMID: 35347592 Free PMC article. Review.
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
Baertsch MA, Mai EK, Hielscher T, Bertsch U, Salwender HJ, Munder M, Fuhrmann S, Dührsen U, Brossart P, Neben K, Schlenzka J, Kunz C, Raab MS, Hillengaß J, Jauch A, Seckinger A, Hose D, Luntz S, Sonneveld P, Lokhorst H, Martin H, Goerner M, Hoffmann M, Lindemann HW, Bernhard H, Blau IW, Scheid C, Besemer B, Weisel KC, Hänel M, Dürig J, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG). Baertsch MA, et al. Among authors: goerner m. Blood Cancer J. 2021 Jan 7;11(1):1. doi: 10.1038/s41408-020-00390-3. Blood Cancer J. 2021. PMID: 33414374 Free PMC article. Clinical Trial.
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
Mai EK, Miah K, Bertsch U, Dürig J, Scheid C, Weisel KC, Kunz C, Munder M, Lindemann HW, Merz M, Hose D, Jauch A, Seckinger A, Luntz S, Sauer S, Fuhrmann S, Brossart P, Elmaagacli A, Goerner M, Bernhard H, Hoffmann M, Raab MS, Blau IW, Hänel M, Benner A, Salwender HJ, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG). Mai EK, et al. Among authors: goerner m. Leukemia. 2021 Mar;35(3):809-822. doi: 10.1038/s41375-020-0976-9. Epub 2020 Jul 20. Leukemia. 2021. PMID: 32684633 Free PMC article. Clinical Trial.
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
Goldschmidt H, Mai EK, Dürig J, Scheid C, Weisel KC, Kunz C, Bertsch U, Hielscher T, Merz M, Munder M, Lindemann HW, Hügle-Dörr B, Tichy D, Giesen N, Hose D, Seckinger A, Huhn S, Luntz S, Jauch A, Elmaagacli A, Rabold B, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Hoffmann M, Hillengass J, Raab MS, Blau IW, Hänel M, Salwender HJ; German-speaking Myeloma Multicenter Group (GMMG). Goldschmidt H, et al. Among authors: goerner m. Leukemia. 2020 Jul;34(7):1853-1865. doi: 10.1038/s41375-020-0724-1. Epub 2020 Feb 7. Leukemia. 2020. PMID: 32034285 Clinical Trial.
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
Goldschmidt H, Baertsch MA, Schlenzka J, Becker N, Habermehl C, Hielscher T, Raab MS, Hillengass J, Sauer S, Müller-Tidow C, Luntz S, Jauch A, Hose D, Seckinger A, Brossart P, Goerner M, Klein S, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Haenel M, Martin H, Lindemann HW, Scheid C, Nogai A, Salwender H, Noppeney R, Besemer B, Weisel K; German Myeloma Multicenter Group (GMMG). Goldschmidt H, et al. Among authors: goerner m. Leukemia. 2021 Apr;35(4):1134-1144. doi: 10.1038/s41375-020-0948-0. Epub 2020 Jul 21. Leukemia. 2021. PMID: 32694619 Clinical Trial.
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.
Klein EM, Tichy D, Salwender HJ, Mai EK, Duerig J, Weisel KC, Benner A, Bertsch U, Akhavanpoor M, Besemer B, Munder M, Lindemann HW, Hose D, Seckinger A, Luntz S, Jauch A, Elmaagacli A, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Raab MS, Blau IW, Haenel M, Scheid C, Goldschmidt H, On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg. Klein EM, et al. Among authors: goerner m. Cancers (Basel). 2021 Sep 28;13(19):4856. doi: 10.3390/cancers13194856. Cancers (Basel). 2021. PMID: 34638344 Free PMC article.
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
Mai EK, Miah K, Bertsch U, Dürig J, Scheid C, Weisel KC, Kunz C, Munder M, Lindemann HW, Merz M, Hose D, Jauch A, Seckinger A, Luntz S, Sauer S, Fuhrmann S, Brossart P, Elmaagacli A, Goerner M, Bernhard H, Hoffmann M, Raab MS, Blau IW, Hänel M, Benner A, Salwender HJ, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG). Mai EK, et al. Among authors: goerner m. Leukemia. 2021 Dec;35(12):3636. doi: 10.1038/s41375-021-01357-4. Leukemia. 2021. PMID: 34785794 Free PMC article. No abstract available.
41 results